Furthermore, improvements, after 3 years of therapy, included an ALT level reduction (p < 0.001), as measured based on noninvasive tests of fibrosis, e.g., NAFLD fibrosis score (NFS) [between-group difference (−0.062); 95% CI: (−0.116)–(−0.008); p = 0.002] and the fibrotic nonalcoholic steatohepatitis index (FNI) [between-group difference (−0.054); 95% CI: (−0.067)–((−0.041); p < 0.001] [29]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.